Norwegian airlines, Company evaluation and long-entry strategy ABOUT
- Low cost airline company that offer nice and comfortable, cheap flights to (especially) Europe and Worldwide destinations.
- Adapting Bitcoin as accepted payment from August.
MANAGEMENT
- One of two major airlines in Norway.
- Been taking a substantial beating during the Coronavirus crisis, risking bankruptcy.
- Change of management last year. Previous management took a lot of irresponsible
expansion risks. Current management is more responsible and have a lot of experience.
Continuous restructuring since takeover.
- Company saved through converting bonds recently, lowering the debt/equity ratio
although the ratio is still high. Converting-action had the company meet loan requirements
set out by the Norwegian government. Now set to survive and hopefully thrive as boarders open.
BALANCE SHEET
- Total Assets - Total Debt = 20.965 B
- Market Cap = 11.542 B
- Price to Book ratio = 0.1535 (in comparison - other airlines: SAS = 1.0348, LHA = 0.4604, UAL = 0.6294, DAL = 1.0739)
- Price to Sales ratio = 0.118 (in comparison - other airlines: SAS = 0.0919, LHA = 0.1276, UAL = 0.1736, DAL = 0.3565)
- Debt to Equity ratio = 14.8798 (in comparison - other airlines: SAS = - 24.6038 LHA = 0.9780 UAL = 2.4877 DAL = 1.6054)
- NOTE: Total debt of approximately 10.0 B has been converted from bond debt to stock shares and is reflected in the Market Cap
noted above, however it is not reflected in the Total Debt since the conversion will not be visible until the 2020 Annual Report.
RISK FACTORS
- Bankruptcy a lot less likely, but may still be possible if the crisis stretches out for a while.
- Total Assets value probably does not reflect actual value if many airlines go bankrupt at the same time since demand for
assets will fall, especially if travel restrictions continue.
- Price is volatile with a one year beta of 2.0667.
- Company is highly leveraged which obviously makes this investment risky, but this will likely be reflected in the profits.
Norwegian Airlines reached its all-time-high back in 2015 with a price of NOK 220 which means that the current value represent
a shave-off of 98.4 % since then.
- Human psychology of Norwegian small scale (private) investors represent a significant contribution to price fluctuations.
VOLUME
- Recent PUMP-UP in volume on the daily (idea post) and the monthly chart (below) signals a massive ramp up by institutional investors.
As you can see, the monthly volume is HUGE in the context of volume history since the start in 2004. We have never seen such wild
volume. CAUTION: wait and see if this is a PUMP-UP-SIGNAL or a WARNING-SIGNAL.
Monthly volume:
TRADING STRATEGY
- The price has been falling on this volume, although not significantly. In comparison, the price fell by approximately 88.1 %
due to the coronavirus crash.
- Wait and see what happens with daily, weekly and perhaps monthly indicators. If parabolic SAR dots start supporting an upwards trend
and we see a shift in configuration of the Exponential Moving Average ribbon, it will be a good time to get into a long position and we can
consider the recent volume pump up to reflect a charge signal.
- Get out if SAR and EMA-ribbon switch direction in momentum, also pay attention to the resistance- and fibonacci-levels.
Macro resistance-levels and -zones to watch out for:
Macro fibonacci-levels:
I you have any questions, feel free to ask me in the comments.
Cheers,
Navigating Shifting Landscapes
Norwegian Air NASIf you want to be a Hobby investor, first tip is to learn TA (Technical analysis)
As you can see here on Monthly chart its a head and shoulder and inside this a Double top. Neckline breaks and confirm the bearish. Now the stock is on last support, good buy?
This chart is for longtrend investors
BGBIO - an intelligent bet on covidBGBIO is a biotech company with focus on cancer treatment.
Like most biotech it is extremely volatile for news, but often fluctuate between key buy and sell zones when no news are evident.
BGBIO is presenting news on their cancer treatment 25th of june.
They are currently first in line to do a free test in ACCORD - the British rushed testing setup for COVID-19
Before news I expect the share to keep bouncing back and forth between the buy zone (established from a large public offering at 37,5 - 50 MUSD) to the sell zone (as seen on TA). BLUE ARROWS
Any movements outside this zone is unlikely before we get more news.
If we do get positive news as to treatment going well, the share could very quickly get an insane pricing (2-3x current price). However, as we have seen from a lot of other companies lately, just starting or finishing test phases without failing = price increase.
I expect such a movement sometime the next two weeks. The CEO has indicated he will let the market know asap when the study starts and I expect that announcement to quickly bounce the price to ~50 NOK before it retraces to the current sell zone. When this happens it will turn into the new buy zone.
1) Go long with a position, you can collect a probable 25% at 50 NOK within 2-4 weeks
2) Play the swing trade between 37-39 and 42-44 with some of your position in the meantime
____________________
3) If for some reason the first phase should not go as planned and their drug will not be suitable for covid, the drug is still very well touted for cancer and has the next potential boost at june 25th
BGBIO / BergenBioBiotech company based i Norway/UK
Listed on OSE
BergenBio`s Bemcentinib now in
UK financed Covid-19 studym, Fast track ACCORD.
Number og study ongoing: 15
3 big:
* ACCORD Covid-19
* Bemcentinib/Keytruda combo whit Merck i NSCLC.
* AML
9 of 15 sponsored studies.
Tecnicaly potent, whit big upside potential. Fair value at the moment 86nok. Archtic Securities.
BerGenBio $BGBIO upgraded target price to 86 NOK from ArcticSecQuote:
"Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly.
Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK 86.
Read-out of the phase 2 study is expected in approx. 6 weeks. Developments will be followed closely."
Source:
www.research-tree.com
OptimistiskKjøpte nå på 0,922 som er nærme forrige bunnivå fra des 2008. Den har stort volum på vei ned så har ikke så store troen på at den holder, men har en ganske god oppside hvis den snur. Brukt Fibonacci for å se på de store nivåene så:
PT1: 3,2
PT2: 5
PTxx: OSV nivåene på FIB
Stoploss på 0.878
Will TEL break the downward trend?A bit longer perspective. See clear downward trend with the current weekly view. Currently trading below both weekly and daily 50MA (W171.53, D156.55) and 200MA (W159.70, D170.85).
Broke previous support line on the 9th of March, bouncing back into the weekly trend (white lines). Will be looking for first checkpoint at break of daily resistance line at blue point. Will be interesting to see whether it can approach the daily resistance line from last top at the intersect with weekly resistance line in the longer time perspective. RSI chart good and high volume the last two-three weeks.
Currently no entry, but will be following this one. The long term support line from 2017 is set at 126.0. Will hopefully bounce back into better times as COVID-19 period is over.
Gladly looking for feedback as I am still learning.